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ABSTRACT
Ribonuclease inhibitor (RI) is an intracellular mammalian protein which binds
vertebrate-specific ribonucleases; this interaction is one of the tightest non-covalent
interactions yet discovered. The biological activity of RI is poorly understood, but it is
thought to regulate the biological functions of ribonucleases, which include initiating
blood vessel growth, maintaining neuron viability, attacking pathogens, and mediating
cell stress responses. RI is also involved in pathways unrelated to ribonucleases,
including interactions with Drosha and PTEN, an anti-tumor protein.
One of the defining characteristics of RI is its oxidation sensitivity, a result of its
unusually high cysteine content.

The oxidation of RI is all-or-none and leads to

complete loss of inhibitory activity; this feature is known to be relevant to at least some
of its functions within the cell.

However, the importance of these cysteines in the

structure, inhibitory activity, and oxidation sensitivity of RI is unknown.
Variants of RI have been created in which sets of cysteines in RI have been
conservatively replaced with other amino acids.

In this study, we sought to

recombinantly express and purify both native RI and the RI variants. Once pure, the
variants were characterized for structural stability, inhibitory activity, oxidation
sensitivity, and structural similarity to wild-type RI. Preliminary data suggest that the
replacement of cysteines leads to an increase in structural stability but a decrease in
inhibitory activity. This is a sign that tight binding of ribonucleases and vulnerability to
oxidation may have co-evolved.
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INTRODUCTION
In 1958, Francis Crick first drew out this famous scheme, defining the flow of
genetic information within living organisms (1):

Figure 1: A sketch from Francis Crick’s personal notes.

If you’ve taken an introductory science class any time within the last 40 years,
you might recognize this as molecular biology’s central dogma. This awe-inspiring
chemical reaction was first sparked into motion billions of years ago and has been
churning on and on ever since. In words, living organisms are able to rewrite the
information contained in our DNA into RNA messengers, which can be translated into
proteins.

Proteins are thought to serve as the grunts of the biological operation, like

little robots, filling thousands of varied roles including digesting complex and diverse
nutrients (2), transporting oxygen in blood (3), keeping skin strong and healthy (4), and
enabling sight, smell, and touch (5) (6) (7). Because of their primary and measurable
role in biochemical functions, proteins have been thoroughly researched. DNA has
gotten plenty of attention as well; we are taught from a young age the importance of our
genes and how they make us who and what we are.
Much like the middle child that it is, RNA has not received the attention it
deserves. RNA is not simply a messenger that reports from the information banks of
DNA to the protein factories of the ribosomes. This misunderstanding long stood for a
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simple reason: DNA and most proteins are considerably more stable than RNA, and
thus were the first biological molecules to be purified and studied (8). However, as
analytical techniques have improved, we have been able to take a deeper look into the
mystery of life. As we do, the significance of RNA is becoming more and more clear.
Specialized forms of RNA are ubiquitous. Transfer RNA (tRNA) and ribosomal RNA
(rRNA) are vital pieces of the protein assembly line (9). MicroRNAs can directly
regulate the expression of genes, and newly discovered circular RNAs add another step
of complexity, by regulating the activity of microRNAs (10). Even more intriguing is the
existence of RNA molecules with enzymatic activity; these ancient “ribozymes” can be
found catalyzing chemical reactions, a job originally thought to be reserved only for
proteins (11). Even in RNA’s classical role as the conduit through which genes become
proteins, its importance should not be underestimated.
To better appreciate RNA’s significance, allow me to take you back in time to a
world that may have existed billions of years ago: the RNA world. RNA is chemically
similar to DNA, including a shared ability to encode genetic information. Some viruses
exclusively use RNA to store their genetic information (12). RNA also can act like an
enzyme, catalyzing reactions. Given this versatility, it is possible that RNA once
performed all of the functions that DNA and proteins perform today. The implications of
this possibility are vast for our understanding of how life may have begun. And it isn’t
so far-fetched! In 2009, the Nobel Prize in Chemistry was awarded to Thomas Steitz
(’62), along with Venkatraman Ramakrishnan and Ada Yonath, for their work in
elucidating the structure and mechanism of the ribosome, the omnipresent and ancient
macromolecular machine that synthesizes proteins from RNA code (13). Their data
confirmed that the ribosome’s activity is actually catalyzed not by its protein structure
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but by the ribosomal RNA contained within it. Thus, it appears that while DNA and
proteins have been stealing the limelight, RNA has been quietly performing the some of
the most vital functions of life.
The diverse types of RNA within the cell, which are still being revealed, can be
regulated and manipulated by proteins known as ribonucleases, which cleave RNA into
smaller pieces. Ribonucleases exist in eukaryotes, prokaryotes, and viruses,
suggesting an ancient origin and an essential role in life (14) (15) (16). One family of
ribonucleases new on the scene, evolutionarily speaking, is known as the vertebratespecific ribonuclease family. These ribonucleases cleave single-stranded RNA at highly
varied rates (17). These RNA-regulating proteins have their own regulator as well,
known as ribonuclease inhibitor.
Ribonuclease inhibitor (RI) is a 49.8-kDa protein found in the interior of cells in
mammals (18) (19) (20). This protein has a non-globular, horseshoe-like structure (21)
(18) (Figure 2). Although different ribonucleases from the vertebrate-specific family are
found fulfilling a wide variety of jobs scattered throughout the body (Table 1), RI is able
to bind to nearly all of them, rendering the ribonuclease dead in its tracks (22).
Although this binding interaction is reversible, it is certainly on any biochemist’s short list
of the tightest protein-protein interactions known (23). Yet, RI is a rather fragile protein–
even the oxygen levels found in the bloodstream are high enough to denature it (24).
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Figure 2: The Ribonuclease Inhibitor “Horseshoe”. 3D ribbon structure of porcine (pig)
RI from (A) top-down and (B) front views. C-terminus shown in orange; N-terminus shown
in pink. Blue represents A-type repeats; yellow represents B-type repeats. The helical
structures on the outside of the “horseshoe” are called α-helices. The arrows on the
interior represent β-strands. Image created using PyMOL from PDB #2BNH. Crystal
structure resolved by Kobe and coworkers (21).
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Ribonuclease inhibitor is more than just a modulator of ribonuclease activity.
Without ribonuclease inhibitor present, vertebrate-specific ribonucleases can cause cell
death (25). Why, then, is such an important protein so easily denatured? In this study,
we will modify the biochemical properties of human ribonuclease inhibitor in order to
investigate the relationship between its oxidiation-sensitive nature and its vital role
within the cell.

Characterization and Structure
Interactions with ribonucleases
RI is able to inhibit the activity of a large number of members of the vertebratespecific ribonuclease family, or RNase A superfamily, of proteins (26). Ribonucleases
from this family are relatively small, composed of about 130 amino acids (27). These
ribonucleases cleave single-stranded RNA via hydrolysis of the phospho-ester bonds
that link together RNA’s backbone (28). RNase A, a prototypical member of this family,
catalyzes this reaction almost as quickly as it can come into contact with RNA through
diffusion; it is “an enzyme limited by physics rather than chemistry” (29). Two histidines
and one lysine make up the active site of vertebrate-specific ribonucleases. Aside from
these three catalytic residues and another six to eight cysteines important to structure,
ribonucleases are considerably diverse, with sequence identities as low as 20% (27).
Even in the face of this divergence, the non-covalent binding interaction between RI and
ribonucleases is exceptional, occurring with femtomolar affinity (23). Eight members of
this family have been isolated from human tissue; another five may exist according to
genetic analyses (Table 1).
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Ribonuclease

Also Known
As

RNase 1

Human Pancreatic
RNase

RNase 2

Eosinophil-derived
neurotoxin (EDN)

Found Ina
Pancreas, kidneys, stomach,
lungs, liver, spleen, endothelial
tissue, urine, blood serum (30)
(31)
b
Eosinophil granules , spleen,
liver, kidneys, placenta, urine
(32)

RNase 3

Eosinophil cationic
protein (ECP)

Eosinophil granules (32)

RNase 4

---

Pancreas, lung, skeletal muscle,
heart, kidneys, and placenta (38)

RNase 5

Angiogenin (ANG)

Liver (40), endothelial cells,
spinal cord (41), cancer cells
(42)

RNase 6

---

RNase 7

---

RNase 8

---

Placenta (53)

---

testes (27); other locations
possible

RNase 9-13
RNase A
BS-RNase
Onconase

f

Bovine Pancreatic
RNase
Bovine Seminal
RNase
ONC;
Ranpirinase;
P-30

b

Lungs, heart, brain, placenta,
liver, skeletal muscle, kidney,
pancreas (50)
Keratinocytes (51); Liver, kidney,
skeletal muscle, heart (52)

Proposed Functions

Binds to
RI? (23)

Maintaining serum viscosity
(32); activation of immune
system (33)

Yes

Activation of immune system
(33); Antiviral protection (34)

Yes

Regulating inflammatory
responses (35);
c
antiviral/bacterial/helminth
protection (36); Induction of
d
apoptosis (37)
e
Angiogenesis , stimulation of
neuronal growth,
neuroprotective (39)
Angiogenesis (43); rRNA
production, cell proliferation
and survival (44); extension
and survival of motor neurons,
neuroprotective (45); cell
stress response (46); cancer
cell proliferation (47) (48);
Protects skin from bacteria
(49)
Unknown.

Yes

Yes

Yes

Yes

Pancreas of bovines (Bos
taurus) (55)

Protects skin from bacteria
(51)
Antimicrobial protection of
placenta (54)
Not known; suspected to not
be ribonucleolytic; may play a
role in male reproduction (27)
Digestion of RNA from
stomach microorganisms (55)

Bovine semen (56)

Immunosupression (56)

No

oocytes of northern leopard
frogs (57)

Cytotoxic in humans; targets
tumor cells (57); used in
cancer therapy (58)

No

Yes
Unknown
Unknown
Yes
g

Table 1: A selection of members of the vertebrate-specific ribonuclease family showing their source and functions, if
known. Ribonucleases shown are found in humans unless otherwise noted.
a
The tissues listed are where the production of these ribonucleases has been detected; however, ribonucleases
have signal peptides that allow them to be secreted from cells (27). Therefore, they may be found elsewhere.
b
Eosinophil granules are vacuoles found in eosinophil granulocytes, a type of white blood cell, which contain toxic
proteins and compounds that are used to attack pathogens. For further reading, see (59).
c
Helminths are parasitic worms.
d
Apoptosis is the self-initiated death of a cell.
e
Angiogenesis is the growth and development of new blood vessels.
f
Genes were discovered in the human genome that pointed to the existence of these 5 ribonucleases; little is yet
known about their activity or function.
g
BS-RNase is found in nature as a dimer, i.e. it partners with another copy of itself. The monomer form does bind
to RI (23) (60).

11
RNase A is responsible for many firsts in the modern understanding of proteins.
The discovery of the effects of boiled pancreas extract on nucleic acids from yeast, in
1920, may have been the first time a protein was shown to serve as an enzyme (a
catalyst to a chemical reaction) (61). In the late 1940’s, Armour, Inc., a hot dog
company, was able to purify RNase A by the kilogram, a feat made possible in part due
to RNase A’s exceptional resistance to high heat and acidity (55) (62). Armour
distributed 10mg samples, for free, to any scientist who requested one. By the early
1960s, this wide availability led to several breakthroughs in the fledgling field of
biochemistry. The catalytic mechanism of RNase A was the first enzymatic mechanism
to be solved to the level of its amino acids (55). The amino acid composition of RNase
A was also discovered before any other enzyme (17).
In 1952, a decade prior to any of these insights into the structure and mechanism
of ribonucleases, Pirotte and Desreux (63) noted that the soluble fraction obtained from
homogenized guinea pig livers was able to inhibit ribonucleolytic activity. By the late
1970s, this activity was found to be the action of ribonuclease inhibitor, which binds to
and inhibits ribonucleases in a 1:1 stoichiometric ratio (64).
The affinity of an enzyme for its inhibitor, or how tightly they bind together, can be
quantitatively represented by a value known as an inhibition constant, or Ki (65).This
value, measured in molarity, represents the concentration of inhibitor required to reduce
the activity of its target by 50%; lower inhibition constants imply a higher affinity
between two proteins. Lee and coworkers (66) used several techniques to detect the
remarkably low Ki for the RI·ribonuclease interactions and the method by which they
interact. First, RI and a target ribonuclease, angiogenin (ANG, or human RNase 5),
were incubated together in a 1½:1 ratio. A large excess of RNase A was added, which
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served as a scavenger for free RI. Aliquots were removed at regular intervals to track
the rate at which angiogenin became free in solution. This was repeated, with ANG and
RNase A switching roles. The Ki for the RI-ANG complex was found to be 7.1x10-16 M,
and the Ki for the RI-RNase A complex was found to be 4.4x10-14 M. This indicates
that RI binds to ANG tighter than to RNase A (66). The addition of cytidine 2’phosphate, a competitive inhibitor of RNase A which binds to its active site, decreased
the association rate between RI and RNase A, suggestive of a competitive mode of
binding (binding blocks the target’s active site) between RI and RNase A (66).
Modifying the active site of angiogenin resulted in a weakening of the RI-ANG complex,
also suggesting a competitive binding between RI and ANG (67).
RI binds ribonucleases tightly, but also quickly (68). This impressively fast rate is
aided by Coulombic attraction, or the attraction between positive and negative charges.
At biological pH, ribonucleases are cationic proteins (are positively charged), and RI is
an anionic protein (69) (70). This leads to RI and its target ribonucleases being brought
together faster than by diffusion alone (71).
In recent years, the determination of the 3D structure of the binding interaction
between RI and angiogenin, eosinophil-derived neurotoxin, RNase A, and RNase has
been determined by x-ray crystallography . Being able to “see” RI binding to its ligands
has provided new insights into what makes RI such an exceptional scavenger of
ribonucleases. From the data provided by these crystal structures, the exact location of
hydrogen bonds and electrostatic interactions that participate in the binding interaction
can be determined (Table 2).
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Ribonuclease

% Identity
with RNase 1*

Ki with
RI (fM)

# Contacts
from RI

# Contacts
from RNase

Surface Area
Buried by RI (Å2)

RNase 1
RNase 2 (EDN)
RNase 3 (ECP)
RNase 4
RNase 5 (ANG)
RNase 6
RNase 7
RNase 8
RNase A
BS-RNase

100
28.4
27.9
40.6
33.3
30.9
31.6
32.4
68.0
70.3

0.29
2.7
◊
4.0
0.7
◊
◊
N.D.
44
9
>2x10

28
42
N.D.
N.D.
30
N.D.
N.D.
N.D.
28
No Binding

23
31
N.D.
N.D.
28
N.D.
N.D.
N.D.
24
No Binding

2802
3438
N.D.
N.D.
2659
N.D.
N.D.
N.D.
2550
No Binding

Table 2: The affinity of RI for various ribonucleases. “N.D.” indicates that a given value has not yet been
determined [and/or published]. Lower Ki values indicate tighter binding between RI and a given ribonuclease.
Table is adapted from Rutkoski et al. 2008 (23) with additional data from Kobe and Deisenhofer 1996 (72).
* % Identity is the percentage of identical amino acid residues at identical positions when two proteins are
compared with each other.
◊ No published Ki exists for the interaction between RI and these ribonucleases. However, ECP has been
shown to be “sensitive” to RI (73), RNase 6 binds to RI in a “very tight” interaction (74), and RNase 7 is
also “sensitive” to RI. (75).

Although RI is a large and repetitive protein, most of the binding interactions
between RI and ribonucleases are concentrated very close to the C-terminus of RI (72)
(74). The ribonuclease residues that participate in the binding interaction are regionally
focused at the catalytic core rather than at any one end (70) (74). This regional
focusing is the general rule, but the specific contacts being made between the residues
of RI and a given ribonuclease are mostly unique. ANG and RNase A both make
extensive contacts with RI, but only hold in common about 1/3 of those interactions.
(74). Additionaly, there is no clear relationship between homology to RNase 1 (which
human RI binds the strongest) and tighter binding (Table 2), which indicates that the
ability of RI to inhibit ribonucleases is based on its ability to recognize unique
characteristics of its targets rather than any structural similarities shared by the
vertebrate-specific family.
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The size and shape of RI also play an important role in ribonuclease binding.
The interface between RI and RNase 1 buries away 2,802 Å2 (1 Å = 0.1 nanometers) of
the surface area of the pair of proteins, including the catalytic core of the ribonuclease
(23). This area is 100 billion times smaller than the period at the end of this sentence,
but for a protein-protein interaction, this is pretty impressive. It’s almost twice the
surface area buried between monoclonal antibodies that bind to proteins (a gold
standard for tight binding) or between barnase and barstar, a bacterial
ribonuclease/ribonuclease inhibitor pair (76). The non-globular horseshoe shape of RI
allows the exposure of 10% more of its surface area than would be expected this
protein, given its mass, allowing for a maximized binding surface (72).
One might imagine RI acts like a gigantic claw, trapping the ribonuclease inside
of it and gripping it from all sides. RI does open wider to accommodate its target, but
much of the ribonuclease binds instead to the top of RI, and some even manages to
escape the “bite” of RI completely (77) (Fig. 3). RI does not have a single hinge point;
rather, its entire structure stretches to accommodate ribonucleases (72).
The parallel β-strands on the interior of RI, which are unusually flat, are a hotspot
for protein binding. They contribute 32% of the residues that bind RNase A, but only
make up 11% of the total protein (77). β-strands may also be responsible for another
protein-protein interaction in RI: dimerization, or the creation of a bound “pair” of RIribonuclease complexes. The N-termini of two RI molecules appear to flip upside-down
to form β-strands which allow the two proteins to stack together (Figure 3). This
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Figure 3: Binding Interactions with RI. The top row of images sho ws a single RI-RNase pair from the top view. RI is shown in green. The bottom
row of images shows a frontal view, including a dimeric RI-RNase pair with RI in gray (The RIa A complex exists as a monomer in free solution
(103)). Note the RI-RNase 1 complex, where this dimerization is most clear. Images created using PyMOL. Crystal structure for RI-RNase 1 from
PDB #1Z7X (70). Crystal structure for RI-RNase A from PDB #1DFJ (72). Crystal structure for RI-Angiogenin from PDB #14AY (74). Crystal
structure for RI-EDN from PDB #2BEX (178).
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dimerization buries a significant amount of additional surface area (1,700 Å2 in the case
of RI-RNase 1) (70). However, it is not known if this dimerization actually occurs in vivo
or if it is simply a consequence of the crystallization process that is used to acquire the
3-dimensional structure of proteins.

Evolution of ribonuclease inhibitor, a leucine-rich repeat protein
Ribonuclease inhibitor belongs to a special class of proteins which contain
“leucine-rich repeats”, or LRRs, in their amino acid sequence. A leucine-rich repeat is a
short amino acid sequence motif that is unusually rich in the amino acid leucine (78).
LRRs are usually 20 to 30 residues long, and in RI, they alternate between 28 and 29
residues (78). The 28-residue LRRs in RI are named “A-type” repeats; the 29-residue
LRRs are named “B-type” repeats (21). LRRs are always found repeating in tandem, as
few as 2 times and as many as 52 times in a row (78) (79) (80).
The LRR sequence motif has been found in over 60,000 proteins from fungi,
plants, animals, bacteria, archaea, and even viruses (81). The LRR motif was first
recognized in a protein called leucine-rich α2-glycoprotein, which was isolated from
human blood serum (79) (82). Ironically, the precise function of this protein still has yet
to be discovered; however, other LRR-containing proteins have since been found with
have a vast array of roles including, but certainly not limited to, neuronal development,
mRNA transport, cell signaling, cell adhesion, and apoptosis (83) (80). In these various
roles, the LRR motif typically contributes to molecular recognition and protein-protein
binding interactions, with the RI-ribonuclease interaction being a prototypical example
(84). In plants and animals, a class of LRR protein receptors has evolved that
recognize and bind molecular features common to bacterial and fungal pathogens,
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allowing a defense response; fungi may have evolved a similar yet unique defensive
system that also relies on LRRs (85). In humans, the correct functioning of LRRcontaining proteins is vital; mutations in over 30 proteins with the LRR motif have been
attributed to diseases including Crohn’s disease, multiple sclerosis, arthritis, and
susceptibility to Legionnaires’ disease (80).
The LRR motif is characterized by a highly conserved segment (HCS) followed
by a variable segment. The HCS typically consists of either the sequence LxxLxLxxNxL
or LxxLxLxxCxxL, where L is leucine, N is asparagine, C is cysteine, and x is any other
amino acid (80). Occasionally, leucine is substituted by other hydrophobic residues
including isoleucine, valine, or phenylalanine; similiarly, asparagine and cysteine can be
occasionally substituted by other polar, uncharged residues including serine, threonine,
and also each other (81). Eight general classes of LRRs have been recognized based
on shared patterns in variable segment (81). These eight classes are “RI-like”,
“SDS22-like”, “Cysteine-containing”, “Bacterial”, “Typical”, “Plant-specific”, “TpLRR” and
“IRREKO” (79). The “IRREKO” class (Japanese for “nested”) was the most recent to be
documented and is closely related to the “SDS22-like” and “Bacterial” classes (81).
With the discovery of the 3D crystal structure of porcine RI in 1993, the structural
role of the LRR motif was brought to light (21). Since then, the 3D structures of many
other LRR proteins have been found. Although the LRRs in these proteins are diverse,
the proteins themselves share very similar structural characteristics (Figure 4).
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Figure 4: The 3D Structures of four other proteins that contain Leucine-Rich Repeats (LRRs), viewed from two angles.
Helical structures are shown in blue; β-strands are shown as white arrows. Note the similarity to RI (Figure 2). Images were
created using PyMol.
A) Single monomer of the protein decorin, which forms a dimer in vivo, from Bos taurus (cow). It is found as a member of the
extracellular matrix and earned its name because it binds to and “decorates” collagen fibrils, which are vital to the integrity
of connective tissue (224). From PDB#1XKU.
B) Internalin, from the bacteria Listeria monocytogenes, a food-borne pathogen that causes listeriosis. L. monocytogenes
uses internalin to bind to e-cadhirin, a cell surface receptor protein, in the intestines; once attached, the bacterial cell then
induces its own phagocytosis into the intestinal cell (225). From PDB#1O6S.
C) Toll-like receptor 3, a member of the toll-like receptor (TLR) family, from Homo sapiens. These proteins function as a part
of the innate immune system, recognizing and binding typical pathogen-related molecules, such as flagellin, a protein from
bacterial flagella, or lipopolysaccharide (LPS), a molecule associated with bacterial cell membranes. Once such a trigger
has been bound, TLRs activate an immune response. Toll-like receptor 3 binds double-stranded RNA, a molecule that is a
sign of a viral infection (226). From PDB#2A0Z.
D) Single monomer of the protein YopM from the bacterium Yersinia pestis, which is responsible for the bubonic plague. In
vivo, YopM forms a tetramer which Y. pestis injects into host cells, where it binds to and interferes with the action of host
immune response proteins (227). From PDB#1JL5.
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Like RI, their shape is curved, with each modular LRR unit contributing a β-strand to the
internal β-sheet on the interior of the curve. On the external surface of the curve, each
unit typically contains a helical structure (79). In RI, this helical structure is an α-helix.
The LRRs in RI, at 28 or 29 amino acids in length, are uncommonly long, and the
exterior portion of more typical LRRs, from 20 to 26 amino acids in length, are too short
to form an α-helix. Instead, these shorter LRRs usually contain other less-bulky
secondary structures such as polyproline II helices, 310 helices, β-strands, and β-turns;
occasionally, short versions of these structures appear in tandem (Figure 5) (86). This
reduced bulk allows other LRRs to relax into their banana-like shape, unlike the more
tightly-wound RI (Figure 4).

Figure 5: The various secondary structures of leucine-rich repeats. Note the variety of
structures found on the external side of each repeat. -helices are in green, 310 helices are in red,
polyproline II helices are in blue, and β-sheets are in yellow. A) A 28-residue LRR from RI. B) A 20residue LRR from YopM. C) A 21-residue LRR from decorin. D) A 22-reisude LRR from InlH. E) A
23-residue LRR also from decorin. F) A 24-residue LRR from Toll-like receptor 3. Figured adapted
and colorized from Bella et al. (86).
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Given that LRR proteins appear throughout the spectrum of biological life, and
even in viruses, it has been argued that all LRR proteins share a common evolutionary
ancestor, descending from one gene that would have existed billions of years ago,
before the branching of lifeforms into separate domains. Due to the observation that the
known LRRs can be sorted into eight tightly-conserved classes that appear in specific
taxa, Kajava (87) asserts that each class of LRRs arose independent of one another
during the course of evolutionary history. Additionally, he points out that the hydrogen
bonding network between LRRs within a protein, which lends to their structural stability,
cannot be formed between LRRs from separate subgroups. However, using a novel
grouping method based on sequence homology, Andrade and coworkers (88) was not
able to divide the various LRR motifs into separate classes as cleanly as Kajava.
Matsushima and coworkers (89) discovered LRR proteins that contain “supermotifs” of
several LRRs from different classes repeating in tandem. These supermotifs contain
LRRs from the typical and bacterial subgroups, but were paradoxically found in proteins
from eukaryotes (89). In addition, the IRREKO class of LRRs appears to have evolved
from a common ancestor also shared by the bacterial and SDS22-like LRR subgroups
(81). Combined, these findings tie together the SDS22-like, bacterial, typical, and
IRREKO LRR classes into one evolutionary family that may contain some human LRR
proteins. This provides support for the theory that LRRs have a common ancestor, but
exactly where RI, which defines its own class of eponymous LRRs, fits in this eons-old
story is not well understood.
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The modular nature of RI also provides clues to its more recent evolutionary
history. The gene for human RI has evolved through the duplication of exons, the
protein-coding segments of our genes. In eukaryotes, genes are made of segments
called exons and introns; the introns are cut out and the exons spliced together to make
the final mRNA transcript which is, in turn, translated into a protein (Figure 6). In the
gene that codes for RI, each internal exon (i.e., excluding the ones at either end) codes
for exactly 2 LRRs: one A-type and one B-type repeat, a total of 57 amino acids (90).
All of the introns are also in the same phase, meaning that if any of the internal exons
are removed or moved around, the LRRs in the remaining exons would still remain
aligned with each other (90). In fact, mutated forms of RI have been expressed with
various internal exons removed; remarkably, these mutants retain inhibitory activity (91).
In addition to their identical length, the internal exons are also homologous with each
other, with 50-60% sequence identity. These observations cement the support for the
exon duplication theory. Haigis and coworkers (90) used various methods of
phylogenetic analysis to show that the internal exons of RI are also extremely stable,
and have not homogenized over time to become so similar to one another. This implies
that the exon duplication event happened very early in the evolutionary history of RI and
the internal exons have remained similar over time.

Figure 6: The exon-intron structure of eukaryotic genes. UTR stands for “untranslated region”; this part of the
mRNA transcript merely flanks the gene and is not part of the code for that mRNA’s corresponding protein. Image
created by Wikipedia user Qef (235) and uploaded in the public domain.
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Another perspective on the evolutionary history of RI can be garnered by
studying the evolutionary history of its target proteins, the vertebrate-specific
ribonucleases. It was originally thought that these proteins were only present in
tetrapods (four-limbed: amphibians, reptiles, birds, and mammals); however, more
recent genetic analyses have allowed for the identification of such ribonucleases in
bony fish, but not cartilaginous fish (92). This divide is thought to be the first major
taxonomic divide in the history of vertebrates, occurring approximately 420 million years
ago, during the Devonian period (93). It may be around this time that the first RNase Alike proteins arose (Figure 7). Thus, except for cartilaginous fish, vertebrate-specific
ribonucleases appear throughout the subphylum Vertebrata; together, this group of

Figure 7: Model of the evolution of modern vertebrates. Note that sharks and other related cartilaginous
fish are the only clade not to express RNase A homologs, hence the likely concurrent evolution of RNase A
homologs and a bony skeleton. Points in time where RI could have arisen (Either alongside the RNase A
family or during the rise of mammals, the only clade from which RI has yet to be isolated) have been
highlighted. Image adapted from Understanding Evolution (234) with permission from the University of
California, Berkeley.
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animals are termed teleostomes. Although these ribonucleasess are highly divergent,
enough of their structure has been conserved since this ancient taxonomic split that
human RI is able to bind to vertebrate-specific ribonucleases found in zebrafish (94).
Humans and zebrafish, both teleostomes, have experienced hundreds of millions of
years of genetic divergence, and yet this RI-ribonuclease interaction has been
remarkably conserved. Oddly enough, human RI does not inhibit vertebrate-specific
ribonucleases isolated from frogs or chicken, suggesting that these ribonucleases have
diverged in some classes more intensely than in others (90).
Given that vertebrate-specific ribonucleases, in the absence of RI to prevent their
activity, are cytotoxic (25), it appears vital for a protein like RI to arise and evolve
alongside these ribonucleases. Yet, the mechanism that various teleostomes use to
inhibit their vertebrate-specific ribonucleases remains to be determined. Other
organisms, including bacteria and protozoans, express both intracellular and
extracellular ribonucleases unrelated to vertebrate-specific ribonucleases; these species
also express inhibitor proteins for these ribonucleases that are equally unrelated to
human RI (95) (96). Hence, the RI/ribonuclease coupling is not a unique schema but
rather a sign that the evolution of an inhibitor to regulate RNA-cleaving proteins is
typical and important. Using the gene for human RI as a search template in the NCBI
biosystems database, it appears that homologs of RI may be present in as distant of
species as Gallus gallus (chicken), Taeniopygia guttata (Zebra finch), and Anolis
carolinensis (Carolina anole, a small lizard) (97) (98) (99). Yet, to date, homologs to
human RI have only been physically isolated from mammals. Thus, it is not known if
the proteins responsible for inhibitory activity in other teleostomes have any structural
similarity to RI (18). Complicating things further is the fact that the ancestry of RI is tied
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to its ancestry as an LRR protein. This places it on a historical timeline that may have
begun long before the rise of eukaryotes, let alone animals or the vertebrate-specific
ribonuclease family.

Cysteine-mediated oxidation sensitivity
The efficacy of RI to bind to and arrest
the activity of members of the vertebratespecific ribonuclease family is remarkable, but
RI has one weakness: oxygen, or more
specifically, reactive oxygen species (ROS)
such as hydroxyl radicals or hydrogen
peroxide (100) (101). This weakness is
derived from its high cysteine content.
Through an oxidation reaction, the thiol groups
from two cysteines form a new covalent bond
known as a disulfide bridge (Figure 8).
Disulfide bridges serve as structural linkers
and are typically found in secreted proteins,
where they aid in maintaining structural

Figure 8: A simplified model of the cysteinecysteine disulfide bridge. Oxidizing agents catalyze
the formation of a bond between two free cysteines in
a protein, forming a structural link.

integrity in the exotic and dangerous
extracellular world. However, in RI, the oxidative formation of these disulfide bonds
leads to a structural collapse and a complete loss of inhibitory function (24). Human RI
contains 32 free cysteines, all of which are free and reduced in the native, active form of
RI (102). This number of cysteines, for a cytosolic protein, is unusually high (24). In
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vitro analysis has shown that the oxidative collapse of RI is cooperative and rapid (24).
The oxidation of only a handful of cysteines leads to the formation of an intermediate
structure, due to the new disulfide bonds. This change in conformation increases the
reactivity of the free cysteines that remain, leading to the full pairing of all of the
cysteines in RI (24).
There is truly something ironic about the oxidation sensitivity of RI. RNase A
owes its early discovery and long, extensive history of research to its remarkable
stability to a wide variety of environments and reagents; had it not been for the
important relationship between RI and RNase A, it may have not been discovered
nearly as early or researched quite as comprehensively, thanks to its contrasting
fragility.

Biological Roles of Ribonuclease Inhibitor
Distribution within the body and within the cell
RI appears to be ubiquitous throughout the body. In mammalian studies, RI has
been found within the cells of many organs, including the kidneys, thymus, esophagus,
testes, placenta, brain, lung, spleen, heart, adipose tissue, skin, and red blood cells (49)
(103) (104) (105) (106) (107) (108) (109) (110) (111). However, RI is not found in
extracellular fluid (108).
The localization of RI within the cell has only recently been revealed. An early
study by Chakravorty and Busch (112) in 1968 found that RI could be found both in the
cytoplasm and in the nucleus. However, in 1972, Roth and Juster (113) failed to find RI
in the nucleus by several methods. Therefore, it had been widely accepted that RI is
found exclusively in the cytoplasm (22) (70). However, the use of modern visualization
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techniques such as confocal microscopy has proved that Chakravorty and Bush were
right all along. In 2011, it was discovered that RI is not localized to the cytoplasm, but
to the nucleus and mitochondria as well (114). This opens up the possibility that
unexplored roles for RI exist throughout the cell.

Role in cell protection against ribonucleases
The cytotoxicity of vertebrate-specific ribonucleases was first discovered over 50
years ago, when it was shown that RNase A could stop the growth of malignant cells
both in vivo and in vitro (115). The therapeutic potential of this discovery was limited,
however, because the required dosages were far too large. Since then, other
vertebrate-specific ribonucleases have been discovered that possess more potent
cytotoxic effects. One of these is bovine seminal RNase (BS-RNase). BS-RNase has
an 81% sequence identity with RNase A, but it holds a unique place within the
vertebrate-specific ribonuclease family (116). Unlike any other known member of this
family, BS-RNase forms a dimer in vivo which exists in equilibrium between two
isomers, M=M and MxM; in the latter, the N-termini of each monomer are interchanged
(117)(Figure 9). BS-RNase has significant anti-tumor activity, which the MxM isomer is
responsible for (117) (118) (119). However, the toxic effects of BS-RNase are not
completely specific. BS-RNase suppresses the immune system, is toxic to embryos,
and causes male sterility (120) (121) (122) (123). These negative attributes may negate
the possible medical uses of this protein.
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Figure 9: 3D Crystal Structure of the MxM isomer of dimeric BS-RNase. Monomers are orange and
cyan, respectively. The helices intertwined into the other monomer’s tertiary structure represent the
interchanged N-termini of each monomer. Image created using PyMol from PDB#1BSR (228).

Another vertebrate-specific ribonuclease with cytotoxic effects is Onconase®,
also known as ranpirnase, P-30, or simply ONC. This protein is currently in
development as a candidate anti-cancer and antiviral drug (124). ONC is found in the
liver of Rana pipiens (common name: northern leopard frog) (125) (126). As mentioned
earlier, vertebrate-specific ribonucleases are cationic (positively charged); ONC’s antitumor selectivity is postulated to be a result of the increased anionic (negatively
charged) nature of the surface of cancerous cells (127). This greater difference in
charge allows for increased translocation of ONC across the cell membrane and is
critical to ONC’s cytotoxicity (128) (71).
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Figure 10: Avoiding the “Intracellular Sentry” RI leads to programmed cell death. Cationic molecules are shown
in blue; anionic structures are shown in red. In A, an RNase is endocytosed by a human cell, aided due to favorable
Coulombic interactions. In B, the RNase enters the cytosol. If it can be bound by RI, such as is the case for all studied
human RNases, then it is inactivated (C). If it cannot be bound by RI, such as is the case for ONC or the BS-RNase
dimer, then it may begin to destroy cellular RNA, leading to cell death (D). Reprinted with permission from Johnson et
al. (71). ©2007 American Chemical Society.

The cytotoxicity of BS-RNase and ONC both appear to be mediated by their
ability to evade RI (129). RI can bind to monomers of BS-RNase, which are not
cytotoxic; however, RI cannot bind to the MxM dimer, which is cytotoxic (130).
Furthermore, variants of BS-RNase which cannot dimerize or be bound by RI are even
more cytotoxic than the wild-type dimer, which suggests that not only is avoiding RI an
important factor in cytotoxicity, but also that the wild-type dimer’s cytotoxicity is
dampened by its occasional dissociation into RI-inhibited monomers (131). ONC lacks
several residues that RNase A and its human counterparts contain, residues which
appear to be important to RI binding; its low sequence identity (only 28%) is postulated
to be responsible for its ability to evade RI (132) (133). G88R RNase A (an RNase A
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variant in which the residue 88, glycine, has been replaced with arginine) displays both
reduced affinity for RI and increased cytotoxicity when compared to wild-type RNase A
(129). Increasing the amount of RI expressed in K562 and HeLa cells (cultured human
cancer cell strains) decreased their sensitivity to G88R RNase A. The silencing of RI
through RNA interference had the inverse effect (25). The relationship between
resistance to inhibition and cytotoxicity has earned RI the title of “intracellular sentry”,
with a proposed biological role of guarding cells from rogue ribonucleases (129).
Without its presence, endogenous ribonucleases that manage to enter the cell could
otherwise be cytotoxic, as appears to be the case when RI-resistant ONC or BS-RNase
are endocytosed (Figure 10).
Whether RI is truly an “intracellular sentry” has been controversial. If RI is the
failsafe that prevents ribonucleases from degrading important cellular RNA, then
silencing RI should make increase the cytotoxicity of ribonucleases. Monti and
D’Alessio silenced the expression of RI in HeLa cells to undetectable levels; this further
increased the vulnerability of these cells to BS-RNase (134). Conversely, this did not
have any effect on the cytotoxicity of RNase A. It was concluded that evasion of RI may
not be the mitigating factor in whether or not a ribonuclease can cause harm, and that
only certain vertebrate-specific ribonucleases are intrinsically cytotoxic. However, it has
been suggested that, even at undetectable levels of RI, the RI-RNase A inhibition
interaction is so strong that the cytotoxicity of RNase A can still be prevented (25).
Conflictingly, engineered dimers of RNase A show cytotoxic effects yet were tightly
bound by RI in vitro, which completely inhibited their RNA-cleaving activity (135).
However, such an RNase A dimer has yet to be found in nature (92). Variants of
vertebrate-specific ribonucleases which were engineered in a way that may mimic
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naturally-occuring post-translational modifications show reduced binding to RI
concurrent with increased cytotoxicity (23). Taken as a whole, the available evidence
suggests that the activity of vertebrate-specific ribonucleases can be potentially toxic,
hence the need for an “intracellular sentry” like RI.

Role in managing oxidative stress
Although the inside of a cell is usually a reducing environment, an increase in the
concentration of ROS can lead to a state of oxidative stress (136). ROS are naturally
produced as a result of ATP production in the mitochondria but can also be generated in
excess by the presence of compounds that lead to the production of excess ROS or by
certain disorders (137) (138). Such oxidative stress can also lead to the breakdown of
RI in vivo. Treatment of LCC-PK1 cells (from pig kidney) with hydrogen peroxide and/or
diamide, an oxidizing agent that specifically targets thiol groups, found a significant
decrease in the activity of endogenous RI (136). The concentration of RI in cells
suffering oxidative stress also decreased significantly faster than in control cells,
independent of mRNA transcript levels; this suggests that oxidized, deactivated RI is
specifically targeted for proteolysis. Whether this process is regulated by the
ubiquitination (molecular tagging) of denatured RI or the specific, direct targeting of
oxidized proteins by the proteosome is still unknown (139).
Glutathione, a 3-residue polypeptide, is the cell’s chief mechanism to maintain a
reducing environment in the cytoplasm. Free glutathione can be oxidized by ROS
within the cell and reduced back to its original state by glutathione reductase (140).
Reduced glutathione is simply a reduced cysteine with a flanking amino acid on either
side, a sign of the antioxidant efficacy of the cysteine residue. As discussed earlier,
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active human RI contains 32 reduced cysteines. Thus, it is possible that RI plays an
important role in regulating the redox state of the cell, especially considering its
ubiquitous nature. Wang and Li (141) showed that RI sourced from cow placenta had
strong antioxidant effects against several ROS, including superoxide anions, hydroxyl
radicals, singlet oxygen, and lipid radicals. The scavenging activity of RI against these
ROS was stronger than that of tea polyphenols, the compounds responsible for green
tea’s supposed antioxidant health benefits (142). These antioxidant effects have also
been found in vivo. When RI was overexpressed in rat glial cells, a significant increase
in cell viability in the face of oxidative injury (caused by hydrogen peroxide) was
reported (143). Mice given injections of RI over the course of 5 days were also better
protected against oxidative liver damage induced by carbon tetrachloride. HUVE
(cultured human endothelial cells) and HeLa cells deprived of RI through RNA silencing
also show a decreased amount of intracellular GSH and an increased amount of
oxidation-induced DNA damage following induced oxidative stress (144). The recent
discovery of the presence of RI within the matrix of the mitochondria, where much of a
cell’s ROS are produced, lends further credence to the antioxidative role of RI (114).
RI also appears to be directly involved in oxidative stress signaling pathways.
Cytoplasmic RI in mouse embryonic fibroblasts is rapidly degraded during oxidative
stress, concurrent with a significant reduction in overall protein synthesis (independent
of eIF2α phosphorylation, a known stress-induced mechanism which reduces protein
synthesis) and an increase in the site-specific fragmentation of transfer RNAs (tRNAs)
(145). This tRNA fragmentation is caused by angiogenin, which cleaves tRNAs within
their anticodon loops to produce specific small RNA molecules known as tiRNAs (146).
tiRNAs inhibit protein synthesis by displacing the eIF4F complex (responsible for
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bringing mRNA to the ribosomes for translation) from mRNA; injection of synthetic
tiRNAs was sufficient to inhibit protein synthesis by 20% (145) (147) (148). Silencing
the expression of RI leads to the production of tiRNAs even in the absence of induced
oxidative stress, while overexpressing RI prevents the production of tiRNAs (46) (146).
It appears that the oxygen sensitivity of RI serves as a cell’s signal that it is under
oxidative stress; once RI has been oxidized and degraded, angiogenin is then free to
create tiRNAs and reduce the rate of protein synthesis, which may increase the
likelihood of cell survival (149). This newly-discovered signaling pathway has yet to be
fully understood.
Although free RI oxidizes and denatures in a complete, all-or-none fashion, the
same is not true of RI while it is complexed with ribonucleases. When porcine RI bound
to RNase A was treated with DTNB, an oxidizing agent, RI was found with 14 of its 30
cysteines oxidized; such an intermediate state cannot be found for free RI (150). In this
partially-oxidized complex, RNase A was only inhibited by 85%. Johnson and
coworkers (151) further confirmed this phenomenon by finding a large increase in both
thermal and oxidative stability when either human or bovine RI were bound to RNase A
(bovine) or RNase 1 (human). If RI plays dual roles, both protecting the cell from
rampant ribonucleases and protecting the cell from oxidative stress, it would then
appear that the former takes precedent. Eukaryotic cells have a vast array of enzymes
and small molecules at their disposal to protect themselves against oxidative stress,
with RI being only one of them (152). On the other hand, RI is the only shield available
against possibly-cytotoxic ribonucleases (151). Thus, the increased resistance to
oxidation when holding on to a ribonuclease is likely a trait selected for to make sure RI
keeps its priorities straight.
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Ribonuclease inhibitor and cancer
Whether or not RI serves to aid in the proliferation or prevention of cancer is still
under investigation. Protecting the cell from oxidative damage is sufficient reason on its
face to see RI as an anti-cancer protein; oxidative damage is closely linked to the
development of cancer (153). Yet, once cancer has developed, RI may actually be
harmful, protecting malignant cells from oxidative damage that could otherwise slow
their growth. Nobel laureate James Watson recently put his weight behind a new
hypothesis that our cultural obsession with anti-oxidants may be harming cancer
patients, as the effectiveness of many cancer treatments relies on their ability to induce
the production of damaging ROS (154). This idea could place endogenous
antioxidants, such as RI, in a new light. Resistance to histone deacetylase inhibitors
(HDACis), a class of drugs which rely on ROS production to slow cancer development,
has been attributed to an upregulation of RI expression (155). Still, RI is more than just
an antioxidant, and has a place in other cellular mechanisms which affect the
development of cancer in opposing ways.
One of these mechanisms is the regulation of angiogenin. Angiogenin may play
a role in the oxidative stress response, but it was originally named for its role in
angiogenesis, or the development of blood vessels. Angiogenin was first purified from
human carcinoma cells in 1985 and was shown to be sufficient to initiate blood vessel
growth (156)(Figure 11). Angiogenin’s RNA-cleaving activity, although weaker than that
of RNase A or RNase 1, is necessary for angiogenesis (157). Equally necessary for
angiogenesis is the translocation of angiogenin to the nucleus, where it serves as a
transcription factor, stimulating the transcription of ribosomal RNA (rRNA) (44) (158),
which is perhaps an ironic function for a ribonuclease. While normal levels of
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angiogenin are important for proper cell
growth and maintenance, abnormally high
levels of angiogenin are found in cancer cells,
where it serves at least two functions:
increasing the level of rRNA to meet the
increased demand for ribosomes to
Figure 11: Angiogenin-initiated blood vessel
development in rabbit cornea. Picture taken 15
days following the implantation of 500 nanograms of
angiogenin. White areas caused by camera flash.
Reprinted with permission from Fett et al. (156).
©1985 American Chemical Society.

synthesize protein, and initiating blood vessel
development to increase the supply of
nutrients to the growing tumor (44) (159)
(160) (161) (162) (163). RI, as a strong

inhibitor of angiogenin, regulates the neovascularization that angiogenin induces (164).
RI has also been shown to slow the growth of tumors, which has been attributed to this
anti-angiogenesis function (165). The presence of RI in the nucleus may also signify
that it is able to police the production of rRNA that angiogenin upregulates (114). RI is
vital in maintaining the careful balance of angiogenin’s proliferative effects, thereby
preventing cancerous cell growth.
New evidence suggests that RI is involved in another cancer-related pathway
that, as of yet, is apparently unrelated to its role either as an inhibitor of ribonucleases
or its antioxidant qualities. Kim and coworkers (166) discovered that cytosolic RI binds
to PTEN, a phosphatase protein with a multitude of anti-tumor functions (167).
Evidence also suggests that RI interacts with the Drosha complex, a protein complex
found in the nucleus which is involved in the processing and maturation of microRNAs
(166). The presence of nuclear RI increases the processing of miR-21, a microRNA
which regulates many tumor suppressor genes, including PTEN; aberrant miR-21
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expression and processing is involved in tumor growth (168). Together, it appears that
PTEN binds RI and prevents it from localizing to the nucleus and associating with
Drosha, thereby decreasing the expression of miR-21. More research is needed to
discover the exact mechanism and relationship between Drosha, PTEN, and RI.
RI has a complicated role in the regulation of malignant cell growth. It has been
found to be downregulated in breast cancer cells, and the silencing of RI expression in
bladder cancer cells increased their growth and potential to metastasize (169) (170).
Additionally, the upregulation of RI expression increased the rate of apoptosis in breast
cancer cells and decreased the invasive potential of melanoma cells (171) (172).
Nevertheless, its ability to block the action of various cancer treatments and its role in
promoting miR-21 processing provides evidence that RI may actually aid in cancer
proliferation.
While research concerning the direct role of RI in cancer development remains
contradictory, the understanding of RI-ribonuclease interactions has still furthered the
development new anti-cancer drugs. QBI-139, a RNase 1 variant currently in Phase 1
human trials, was specifically designed to be cytotoxic by evading RI (173) (174).

Other biological roles
The number of important functions attributed to vertebrate-specific ribonucleases
continues to rise. As it does, the possible roles RI may play in vivo increases in
tandem. Many of these roles involve angiogenin, a versatile ribonuclease. For
example, RI is overexpressed in the placenta of women with pre-eclampsia; this may be
a sign that angiogenin is being improperly inhibited, causing the failure of correct blood
vessel development that characterizes this disorder (175). Angiogenin also plays an
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important and newly discovered role in the proper growth and maintenance of neurons,
and mutations in the angiogenin gene have been reported in patients with amyotrophic
lateral sclerosis (ALS), a neurodegenerative disease (41) (45) (176). This discovery
may foretell a regulatory role for RI in neuronal development as well. RNase 4 has also
been discovered to share many functions with angiogenin (RNase 5), including
angiogenesis and the regulation of neuronal development and vitality, broadening the
possible importance of RI in these regulating these tasks (39).

Investigating RI by Constructing Oxidation-Resistant RI Variants
The biological roles that have been discovered for RI revolve around two of its
defining characteristics: its potent inhibition of vertebrate-specific ribonucleases, and its
vulnerability to denaturation by ROS. These two characteristics may be fundamentally
intertwined, arising from the same amino acids. On the contrary, it is also possible they
arise from unrelated regions of the protein, making it imaginable that a modified version
of RI could continue to bind ribonucleases while being immune to oxidation, or vice
versa. Learning more about the relationship between these functions could provide us
with hints about the evolutionary history of RI and the biological importance these
functions hold within living organisms. In this study, we seek to learn more about the
role of RI’s oxidation-sensitive Achilles’ heel: its cysteines.
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Manipulating RI: where and how?
To learn more about the role of cysteines in human RI, modified versions of this
protein have been designed in which sets of these cysteines have been replaced. Five
repeating cysteine positions exist in RI: positions 10, 17, and 21 in the A-type repeat,
and positions 21 and 29 in the B-type repeat (Figure 12) (22). In addition, RI contains 6
other cysteines that do not appear in any pattern. Six variants of RI were designed by
Dickson and Krawicz in which substitutions were made for the cysteines that fit into
each of these patterns (Table 3) (177).

Figure 12: The Various Patterns of Cysteine’s Appearance in the Secondary
Structure of Human RI. Here, the amino acid sequence of RI has been formatted to
show the alignment of each LRR module. The cysteines in RI can be grouped into
several clear patterns: A10 cysteines, in orange; A17 cysteines, in light green; A21
cysteines, in pink; B21 cysteines, in dark green; and B29 cysteines, in blue. Cysteines
shown in red do not fit into any repeating pattern. Image from Krawisz (177).
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Variant Name

Cysteines
Replaced

Replaced With

A10

Cysteines at A10
Position

Serine

A17

Cysteines at A17
position

Valine

A21/B21

Cysteines at A21
and B21 positions

Rationale

In β-turn, where it may be
forming H-bond with
backbone carbonyl (74).
Serine replaces –SH with
-OH, maintaining H bond.
Serine also at this position
in other LRRs. (84)
Part of hydrophobic, nonsolvent-exposed core;
hydrophobic residues at
this position in other LRRs
(84). Conserves the bulk
that the replaced sulfur
atom provided.

Serine

Located in α-helices, is
minimally solvent-exposed;
therefore, a hydrophilic
–OH containing residue
was used (74).

B29

Cysteines at B29
position

Threonine

Located in β-turn, similar
to A10 cysteines.
Threonine was chosen
instead of serine due to its
appearance in this position
in other LRRs (84).

Non-repeating

Cys11, Cys29,
Cys74, Cys95,
Cys328, Cys408

Various (See
Legend)

Conservative substitutions
made as described in text.

Cysteine-Free

All

As Shown Above

---

Table 3: The Design of Six RI Variants with Substitutions for Cysteine.

Residue conservation from

other LRRs based on sequences from Stumpp et al. (84). Structural information based on crystal
structure of human RI bound to angiogenin (74).
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The substitutions made at each site were carefully chosen in an attempt to
maintain the native structure of RI. Structural data available from the crystallization of
RI bound to angiogenin by Papageorgiou and coworkers (74) and an extensive analysis
of amino acids conserved at these positions in other LRR proteins performed by
Stumpp and coworkers (84) provide the basis for the decisions that were made in
designing the variants. Cysteines at the A10 position are located in a β-turn and are
solvent-exposed (in contact with the polar aqueous solution around the protein) and
other LRRs contain polar residues here, including asparagine, threonine, and serine.
For this reason, serine was chosen to replace the cysteines at the A10 position.
Cysteines at the B29 position are also in a β-turn, but were instead substituted with
threonine based on its appearance at this position in other LRRs. The cysteines at the
A21 and B21 positions are in similar structural positions within α-helices, and were
combined into one variant, in which they were substituted with a polar amino acid,
serine, based on their solvent exposure. Cysteines at the A17 position were replaced
with the hydrophobic amino acid valine based on this residue’s conservation at this
position in other LRRs and its position in the hydrophobic core of RI. The cysteines
replaced in the “non-repeating” variant do not share similar structural roles. Cysteines
11, 29, 74, and 408 are solvent-exposed; nevertheless, they were replaced with alanine,
in order to avoid increasing the polarity near the N-terminus and inducing any nonspecific binding interactions. Cysteine 95 is in a similar position; it was replaced with a
threonine to conserve bulk in this region. Cysteine 328 is within an α-helix and thus was
also replaced with a threonine to conserve possible hydrogen bonding interactions.
Cysteine-free RI contains all of the aforementioned substitutions.

40
While two cysteines in RI, Cys11 and Cys408, have been shown to be contact
residues in the binding of various ribonucleases, it is possible that other cysteines may
also be involved in more transient yet still significant interactions (72) (74) (178).
Therefore, until each variant is fully characterized, it is not possible to know what effects
each substitution for cysteine may have on either the structure or the function of RI.
Noting that neither Cys11 and Cys408 are in one of the regular, conserved cysteine
positions in their respective modules, one may hypothesize that the conserved
cysteines in each module are important for the maintenance of secondary structures,
while the non-repeating cysteines are free to form hydrogen bonds or van der Waals
interactions with ribonucleases (19). It also may be true that the cysteines at the A10
and A17 positions are most vital for structural stability, given the relatively high
frequency of cysteine conservation at this position throughout the modules of RI. The
B29, B21, and A21 positions contain a cysteine residue at lower frequencies, in that
order (19). However, at none of the aforementioned positions is cysteine present in
every module of RI; thus, it may be possible to replace each cysteine at these positions,
as we have done, and maintain the same protein structure. Once these variants have
been expressed and purified, they will be characterized for their ribonucleolytic activity,
their thermal and oxidative stability, and their conservation of structural components in
comparison to wild-type RI.

Optimizing Expression and Purification of Recombinant RI
Difficulty of RI purification
The successful study of a protein in vitro requires two major steps: its production
and its purification. This is equally true for RI, but it is not as easy as your everyday
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protein. While RNase A is expressed in bovine sources in large quantities and can be
purified from high heat and low pH conditions, RI is both less abundant and far more
fragile. First, a source with adequate amounts of RI is required. In the past, RI has
been purified from homogenized placenta; this is not an option when it comes to
procuring variants of human RI (103). Presently, a recombinant expression system, in
which the gene for RI is transformed into easily-grown cells such as common bacterial
and yeast strains, is a much more popular choice. Second, the labile nature of the
highly oxygen-sensitive structure of RI means that care must be taken to maintain
reducing conditions and low oxygen concentrations at all times during the purification
(179). Some expression protocols for RI have required 4 liters of recombinant bacterial
culture simply to acquire a single milligram of purified RI, which has led some
researchers to resort to attempting RI expression in eukaryotic insect cells (180) (181).
In contrast, methods exist to purify over 100mg of RNase A from a single liter of culture
(182).
In this study, much time has been devoted to optimizing an expression and
purification system for human RI. A bacterial expression system in Escherichia coli has
been chosen, due to the ease and affordability of culturing these cells in large
quantities, the large number of E. coli strains that have been developed for protein
expression, and the large knowledge bank that exists about optimal growing conditions
for this model species. Other steps have been taken to ensure a maximum yield for this
difficult, elusive protein.
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MBP as a solubility enhancer
While the homogenous overall molecular structure of DNA makes the purification
and processing of various genes simple and generalizable, the diverse chemical nature
of the proteins they encode necessitate the development of a unique purification
protocol for each new target. An indispensable tool in increasing the throughput and
ease of protein purification has been the use of affinity tags. Affinity tags are auxiliary
proteins or short polypeptides that are expressed together as a single product (a fusion
protein) with a protein of interest; the affinity
tag usually has some intrinsic quality that
makes it easy to purify (183). This intrinsic
quality sets a fusion protein apart from the
thousands of other proteins that may be
expressed within a cell. Maltose-binding
protein (MBP) is a common affinity tag with
an ability to bind to maltose or amylose,
which can be attached to a resin capable of
isolating MBP fusion proteins to 70-90%
purity (184) (185) (Figure 13). MBP-fusions
also tend to display impressive increases in
solubility over wild-type target proteins (186)
(187). Low solubility of expressed proteins
in E. coli has been a major roadblock for

Figure 13: Expression and Purification of MBP
Fusion Proteins. A target gene, in this case human
RI, is spliced into a commercially-available MBP vector
plasmid (circular ring of DNA). In E. coli, this plasmid
then expresses an MBP-RI fusion protein, which can be
purified from cell lysate due to MBP’s binding to
amylose. RI is then be cleaved off by the use of a
specific protease, such as enterokinase. The target
protein can be purified from a mixture with MBP by ion
exchange chromatography. Image reprinted from
(2013) www.neb.com from New England Biolabs (229).
©2013 New England Biolabs.
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high expression and purification yields (188). This is especially true for RI, which is not
only poorly soluble when expressed alone in E. coli, but also is not efficiently recovered
from its insoluble form. Yields of over 30mg of soluble, active RI per liter of culture have
been reported via the use of an MBP-fusion vector along with production at low
temperatures (189). For this reason, a cleavable MBP fusion protein vector was chosen
for the expression of human RI in this study.

Chaperones as co-expression partners
Another secret weapon that can increase the expression of active, soluble RI in
E. coli is the co-expression of chaperone proteins, which aid in the proper folding of a
target protein (190). Chaperones from E. coli named GroEL and GroES are commonly
over-expressed to improve folding of recombinant proteins. In vivo, 14 monomers of
GroEL form together in a large, double-ringed barrel-like structure, which is capped by a
ring of 7 GroES monomers (191)(Figure 13). It is thought that this barrel structure
encapsulates unfolded or misfolded proteins through hydrophobic interactions, providing
a favorable environment for their folding; yet, the GroEL/ES complex mediates the
folding of proteins that are too large to fit inside, leaving their complete mechanism of
action unknown (192) (193). Co-expression of GroEL and GroES alongside wild-type
RI has allowed for the production of up to 25 mg of active, folded protein per gram of dry
cell weight (194). For this reason, GroEL/ES co-expression will be incorporated into the
RI expression protocol in this study.
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Figure 14: The Structure of the GroEL/ES Chaperone Complex. A) 14 monomers of GroEL (chaperonin
60) join together to form a tetradecamer barrel (green), capped by a heptamer ring of GroES (chaperonin 10).
B) A computer model of the 3D structure of the GroEL/ES complex; above, a view down into the interior of the
barrel-like structure. Image reprinted from Ranford et al. (230).

Manipulating redox conditions to optimize RI production
Finally, although cells are usually quite robust at internally maintaining a reducing
state, the high oxidation sensitivity of RI can still lead to a significantly reduced yield in
standard shake-flask cultures. This concern was addressed by Šiurkus and Neubauer,
who were able to significantly improve the recovered amounts of active wild-type RI by
spiking the culture media with DTT, a powerful reducing agent, and reducing the
incubation temperature from the standard 37°C (body temperature) to 22°C (room
temperature) (195). They theorize that the solubility of the expressed RI is increased
not only by DTT’s antioxidant potential, but also by the slowed rate of expression
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caused by the combination of low temperatures and the toxicity of the high levels of
DTT used. Because of the increased yields reported via this protocol, DTT-mediated
regulation of the shake-flask cultures’ redox state will be used in this study, along with a
reduced expression temperature.

Characterizing RI and RI Variants: Activity, Structure, and Stability
The goal of our RI variant design is to reduce the oxidative sensitivity of RI while
maintaining activity and structure. While care was taken to make conservative
substitutions for cysteine at each of its positions in RI, it’s not possible to know the exact
effects of these substitutions on paper. Likewise, the impact each substitution may
have on the oxidative stability of RI is not apparent. Therefore, once expressed, each
variant will be evaluated for its maintenance of inhibitory activity, its resistance to
oxidation-induced inactivation, its thermal stability, and its structural similarity to wildtype RI. This will allow us to evaluate the contribution to these characteristics made by
the cysteines found at each conserved position.

Determining the inhibitory activity and oxidative resistance of RI variants
As discussed earlier, the activity of a competitive inhibitor against its enzyme
target is represented by a value known as an inhibition constant, or Ki. This value
represents the concentration of inhibitor which is able to reduce enzymatic activity by
50%.

To find the Ki of each variant, we will measure the activity of RNase A in its

presence using a hypersensitive substrate whose cleavage can be detected
fluorescently in real time (196). This fluorogenic substrate, 6-FAM-dArUdAdA-6-
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TAMRA, contains a chain of nucleotides featuring the same cleavage site for RNase A:
a ribonucleotide followed by a deoxyribonucleotide, 5’ to 3’ (Figure 15). The detection
of this cleavage is possible due to a Förster resonance energy transfer, or FRET,
interaction between the FAM (6-carboxyfluorscein) and TAMRA (6carboxytetramethylrhodamine) fluorophores at either side of the molecule. The
emission range of FAM overlaps with the excitation range of TAMRA, allowing the
energy absorbed (as light) by the FAM to be transferred to TAMRA rather than released
as light in FAM’s emission spectrum (Figure 16) (197). The nucleotide backbone of 6-

Figure 15: The molecular structure of 6-FAM-dArUdAdA-6-TAMRA, a sensitive substrate for detecting RNase
activity. The nucleotide backbone allows for TAMRA to be held in close enough proximity to FAM to quench its
fluorescence. The 3’ phosphate group on the ribonucleotide, Uridine, presents a bond scissile by members of the
vertebrate-specific RNase family. Cleavage of this bond allows FAM to move freely from TAMRA, bringing an end to
the quenching of its fluorescence. Modified from Kelemen et al. (196).
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FAM-dArUdAdA-6-TAMRA holds FAM and TAMRA close enough together to allow a
FRET interaction to occur; however, in the prescence of an active ribonuclease, this
backbone is severed, and the excitation of the freed FAM instead results in the release
of light at FAM’s emission wavelength. Therefore , monitoring the gradual increase of
light emitted at this wavelength when a ribonuclease is incubated with 6-FAMdArUdAdA-6-TAMRA allows the quantification of that ribonuclease’s enzymatic activity.
The inhibitory activity of RI and RI variants can be measured using the same
assay. The decrease in the rate of the cleavage reaction, due to inhibition of the
ribonuclease by sequential additions of RI, causes a detectable reduction in the rate of
increase of fluroescence by the cleaved FAM fluorophore, allowing for the calculation of
a Ki value. This same assay can be used to quantify the oxidative resistance of the
variants of RI that we have created. If the variants of RI that we have created are more

Figure 16: A simplified model of Förster resonance energy transfer. When an isolated fluorophore (A) is
excited by light at or near its excitation wavelength (its excitation spectrum), it releases light of a lower energy, or
of a longer wavelength, at or near its emission wavelength (its emission spectrum). When the emission spectrum
of one fluorophore overlaps with the excitation spectrum of a second fluorophore that is in very close proximity
(B), the emission of the excited fluorophore is quenched, as the energy is instead transferred to the second
fluorophore. The second fluorophore then releases this energy as light within its own emission spectrum.
Excitation and emission wavelength data for FAM from Mineno et al. (231); data for TAMRA is shown as listed by
Sigma-Aldrich (232).
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oxidation-resistant than wild-type RI, the impact of hydrogen peroxide on the variants’
inhibitory activity should be decreased relative to wild-type RI. Consequently, this assay
will allow us to report on both the activity and oxidative resistance of the RI variants we
have produced.

Measuring thermal stability: Is it hot in here, or is it just me?
Proteins are perhaps the most intricate pieces of chemical origami that exist in
the natural world. The present structure of RI in humans is the result of hundreds of
millions of years of evolutionary fine-tuning. This configuration is not set in stone;
indeed, as already discussed, reactive oxygen species pose a lethal threat to the
structure of RI. However, heat can pose a threat to RI as well. At a certain
temperature, known as the melting temperature or Tm, a protein will succumb to
enthalpy and its ordered structure will unfold (198). The more stable the non-covalent
interactions are within a folded protein, the higher the Tm value is.
The metamorphosis of a protein structure that occurs at its Tm can be exploited to
analyze that protein’s structural stability. The unfolding of a protein leads to the
exposure of hydrophobic residues which, in the folded state, are typically buried within
its structure, away from the water surrounding it. A number of fluorescent dyes have
been discovered whose emission intensifies significantly when bound to the
hydrophobic regions of protein; the considerable increase of exposed hydrophobic
residues during protein unfolding means that this process can be detected by a
concurrent increase in the fluorescence of these dyes (199). This phenomenon has
been put to use in several studies to evaluate the stability of proteins (200) (201) (202)
(203) (204) (205). The assay which takes advantage of this fact has come to be known
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as differential scanning fluorimetry and can be performed using a real-time PCR
machine, a device normally used to quantify nucleic acids. This screening method will
allow us to identify the Tm of each of the RI variants we have created, thereby giving us
a measure of the relative stability of the folded structure of each variant.

Comparing structures using circular dichroism spectroscopy
For proteins, structure is function. The 3-dimensional placement of the atoms in
a protein will directly affect how it binds or interacts with other molecules. Even subtle
changes in a protein’s conformation will inevitably modify its activity. While we have
altered several of the amino acids in RI, we have done so with the intention to not
disrupt its structure. We must find a way to show that we have been successful in this
regard or else we cannot associate any of the altered characteristics of our variants
exclusively with the substitutions we have made.
One established method to demonstrate the conservation of protein structure is
circular dichroism (CD) spectroscopy. CD spectroscopy makes use of circularly
polarized light, or light whose electric field vector draws out a helix as it travels through
space (Figure 18). Asymmetrical secondary structures such as α-helices and β-strands
absorb left- and right-handed circularly polarized light unequally; this phenomenon is
known as circular dichroism (206) (207) . This differential absorbance can be detected
by a spectrophotometer and used to approximate the fraction of a protein that is the
aforementioned secondary conformations (208). Changes in the absorbance of
circularly polarized light, or the CD spectrum, between a wild-type protein and a variant
that has been produced via site-directed mutagenesis are indicative that the mutation
has produced a significant change in protein structure (209).
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Figure 18: The mechanics of circularly polarized light. The electric field vectors of
light that is circularly polarized have a constant magnitude but rotate in one direction to
form a circle. In the direction of propagation, the vectors appear to draw out a helix.
Figure reprinted with permission from HyperPhysics (233) © 2013 C.R. Nave.

We know that RI now finds itself in the midst of several pathways that are tied to
pathologies such as cancer in occasionally paradoxical ways. The evolution of its
abundant number of cysteines may have lent RI its fragility, lent it its incredible binding
capabilities, both, or neither; how these characteristics play into its biological roles is a
mystery. This assay, along with those described above, will allow us to collect
important data about the nature of RI and the cysteines it contains.

MATERIALS AND METHODS
General Materials
All chemicals used were of reagent grade. All plasmids were transformed into
and propagated in DH5-alpha E. coli (prepared at Lawrence University) grown at 37°C
by standard protocol. LB media contained 10g tryptone, 5g yeast extract, and 10g NaCl
per liter. TB media contained 12g tryptone, 24g yeast extract, and 4mL glycerol per liter
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with KH2PO4 added to 17mM and K2HPO4 added to 72mM. Plasmids were isolated via
miniprep purification (Qiagen; Hilden, Germany) using manufacturer’s guidelines. Precased SDS-PAGE gels were 4-20% (Bio-Rad; Berkeley, CA). Primers were customsynthesized by Integrated DNA Technologies (Coralville, IA). Sequencing reactions
were performed at the DNA Analysis Facility on Science Hill at Yale University (New
Haven, CT).

Development of wild-type RI and RI variant expression constructs
The original wild-type human RI gene was obtained from the lab of Ronald T.
Raines at the University of Wisconsin-Madison. This gene and partially-completed
versions of each variant gene were previously cloned into vector pET19-b (EMD
Millipore; Billerica, MA).
Poor purification of RI from the pET19-b expression system led us to sub-clone
into a maltose binding protein (MBP) fusion vector, pMAL-c5G (New England Biolabs;
Boston, MA). Wild-type and variant RI genes were removed from pET19-b+RI via
double digestion with BamH1 (Promega; Madison, WI) and Nde1 (New England
Biolabs) in solution with BSA and NEBuffer 3 (New England Biolabs; Boston, MA) at
37°C. Restriction enzymes were brought to 5% (v/v) of supplied concentration via
repeated addition to reaction mixtures over the course of 3 hours. The destination
vector, pMAL-c5G, was digested simultaneously with the same restriction enzymes.
Following digestion, the linearized pMAL-c5G was treated with Antarctic phosphatase
(New England Biolabs; Boston, MA) in the supplied buffer for 15 minutes at 37°C to
prevent auto-ligation.
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Digestion reaction mixtures were concentrated down into a small volume using
either the DNA Clean & Concentrator-5 or DNA Clean & Concentrator-25 kit (Zymo
Research; Irvine, CA). Eluted samples were mixed with DNA loading dye and digested
products were then separated via electrophoresis using a 1% agarose gel containing
GelRed stain (Biotium; Hayward, CA). Slices of the gel containing bands corresponding
to the RI gene (~1500bp) and linearized pMAL-c5G vector (5721bp) were excised using
a clean razor blade to isolate the desired digestion products. DNA was purified from the
agarose gel using the QIAquick gel extraction kit (Qiagen; Hilden, Germany). Samples
were then further concentrated using the DNA Clean & Concentrator-5 kit. DNA
concentration was measured using a NanoDrop 2000 UV-visible spectrophotometer
(Thermo Fischer Scientific; Waltham, MA).
Ligation reactions were performed using T4 DNA Ligase (Promega; Madison, WI)
using LigaFast buffer (Promega; Madison, WI). Reactions were performed using either
a 1:1, 1:2 or 1:3 mole-to-mole ratio of linearized vector to RI (or RI variant) gene insert.
Ligation reaction was allowed to proceed at room temperature for 15 minutes, after
which 1µL of each reaction mixture was transformed into DH5-alpha E. coli.
Transformed cells were plated on LB agar with either 200µg/mL ampicillin or 50µg/mL
carbenicillin and incubated overnight at 37°C.
DH5-alpha colonies that appeared after overnight incubation were qualitatively
screened to check for the presence of the insertion of a gene into pMAL-c5G using
PCR. Colonies were resuspended in 75-100µL of double-distilled water; 1µL of this
resuspension was added to a 20µL PCR reaction mixture containing GoTaq Flexi DNA
polymerase (Promega). This reaction used a forward primer (“pMAL FWD”) that binds
roughly 100bp upstream of the RI gene and a reverse primer (“pMAL REV”) roughly

53
100bp downstream of the RI gene; both sites are located within the pMAL-c5G vector.
Following PCR amplification, reaction products were separated on a 1% agarose gel
containing GelRed stain; colonies which contained pMAL-c5G+RI showed a band at
roughly 1700bp. Diluted colony samples with positive results from this preliminary test
were then used to inoculate 5-10mL of LB media; pMAL-c5G-RI was then isolated from
this culture via miniprep purification. Proper insertion of the RI gene was validated by
DNA sequencing.
Issues with digestion of the fusion protein expressed from pMAL-c5G-RI led us to
sub-clone once again into a new vector, pMAL-c5E, by repeating the above procedure
for all seven genes (wild-type plus the six variants).
Mutations and incomplete variants were detected via analysis of the sequence
data. The A21/B21, A10, cysteine-free, and non-repeating variants all required repair
due to various mutations. Unfortunately, the A17 variant was lost by previous students
and will need to be reconstructed. The necessary site-directed mutagenesis was
performed using the QuikChange Lightning kit (Agilent; Santa Clara, CA). Briefly,
mutagenesis primers were designed to make point mutations at the desired site in each
gene while avoiding mis-priming at other locations. Mutagenesis, DpnI digestion of the
template DNA, and transformation of mutated plasmid were performed according to the
product manual. Correct mutagenesis was validated by DNA sequencing.
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Expression and crude purification of RI and RI variants
Preliminary expression protocols were tested and refined by transforming pET19b-RI into BL21(DE3) E. coli (Lucigen; Middleton, WI). Expression of the RI from pET19b-RI in BL21(DE3) is under control of the lac repressor. Transformed cells were used to
inoculate small (5-10mL LB containing 50µg/mL carbenicillin) starter cultures which
were then (while in log-phase growth) used to inoculate 1-liter cultures of LB autoinduction media, which prevents expression from pET19-b-RI until the culture is in logphase growth (210).
After induction, 1-liter cultures of BL21(DE3) used for RI expression were
pelleted via centrifugation at 7000xg for 30 minutes. Cell pellets were resuspended in
a minimal volume (5-20mL) of lysis buffer (20mM Tris HCl, pH 8.0; 100mM NaCl; 10mM
EDTA; 1mM DTT) and incubated with 0.1mg/mL lysozyme and 1% (v/v) Halt protease
inhibitor cocktail (Pierce; Rockford, IL) for 30 minutes at room temperature. Cells were
then sonicated (40% power, 3x15 seconds) to complete lysis. Lysate was centrifuged
to separate soluble and insoluble fractions for 30-60 minutes at 13,000xg.
RI was isolated from soluble lysate using Ni-NTA resin microcentrifuge spin
columns (Qiagen; Hilden, Germany). The resin was pre-equilibrated with 1200µL NiNTA binding buffer (50mM NaH2PO4, 500mM NaCl, 20mM imidazole, 1mM DTT)
Clarified lysate was applied to the column, which was then washed with 1200µL of
binding buffer. RI was eluted from this resin using 200µL of binding buffer containing
100mM imidazole.
Expression of wild-type RI as a fusion protein with MBP as the fusion partner was
tested and refined in HI-Control 10G, C41(DE3), C41(DE3)-pLysS, C43(DE3), and
C43(DE3)-pLysS E. coli strains (Lucigen; Middleton, WI). These cells were transformed
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with pMAL-c5G-RI. Strains not containing the pLysS plasmid (which codes for
chloramphenicol resistance) were also transformed with pGro7 (Takara; Otsu, Japan), a
plasmid coding for GroEL/ES chaperone proteins along with chloramphenicol
resistance. Transformed cells were used to inoculate starter cultures (5-10mL LB,
50µL/mL carbenicillin, 25µg/mL chloramphenicol) which were used to inoculate 1 liter of
media in a Fernbach flask. Two types of media were tested: TB media and “RI minimal
media”, inoculated with bacteria after following the protocol below (Table 4).
RI Minimal Media
BEFORE AUTOCLAVING (PER 1L)

AFTER AUTOCLAVING (PER 1L)

Trace Element Solution (per 1L)

Reagent

Amount

Reagent

Amount

Reagent

Amount

(NH4)2SO4

2.68g

glucose

10-15g

CaCl2·2H2O

0.50g

Na2SO4

2.00g

1.0M MgSO4

3mL

ZnSO4·7H2O

0.18g

NH4Cl

0.50g

1.0M Thiamine HCl

100µL

MnSO4·H2O

0.10g

K2HPO4

14.6g

trace element sol’n

2mL

disodium EDTA

20.1g

NaH2PO4·H2O

3.60g

carbenicillin

50mg

FeCl3·6H2O

16.7g

(NH4)2-H-citrate

1.00g

chloramphenicol

25mg

CuSO4·5H2O

0.16g

Pure H2O

to 1.0 L

CoCl2·6H2O

0.18g

(Adjust pH)

pH 7.00

Table 4: Protocol for the preparation of RI minimal media. Trace element solution is prepared separately and
should be sterile-filtered before use.

RI minimal media is based on the mineral salt media used by Šiurkus and Neubauer
(194). Inoculated TB media and RI minimal media cultures were incubated (37°C,
220rpm) to an OD600 of 0.5, as detected by a Varian Cary 50 UV-visible
spectrophotometer (Agilent; Santa Clara, CA). At this point, the expression of
GroEL/ES was induced by adding 0.4g/liter of L-arabinose. 2 hours following GroEL/ES
induction, incubation temperature was reduced to 22°C and the expression of MBP-RI
was induced by addition of IPTG (a lactose analog) to a final concentration of 1mM. 2
hours following MBP-RI induction, DTT was added to a final concentration of 12mM.

56
Cultures were allowed to grow for another 2 hours, at which they were pelleted (7000xg,
30 minutes). SDS-PAGE samples were collected prior to induction of GroEL/ES, prior
to induction of RI, and prior to final centrifugation.
Cell pellet was resuspended in 20-40mL (final volume) of lysis buffer and
transported on ice to University of Wisconsin-Oshkosh for lysis via a French press. Halt
protease inhibitor cocktail or PMSF (a protease inhibitor) was added to each
resuspension immediately prior to lysis. Lysate was centrifuged (49,000xg, 60-90
minutes) to separate soluble and insoluble fractions. SDS-PAGE samples were
collected from the total lysate (total cell extract) and from the soluble lysate.
Later MBP-RI purification was performed using via FPLC using an MBPTrap 5mL
FF column (GE Life Sciences; Fairfield, CT), which binds MBP. FPLC purification was
performed at 4°C. The column was pre-equilibrated with 5 CV of amylose binding
buffer, after which the clarified lysate was applied. The column was then washed with 8
CV of amylose binding buffer, after which MBP-RI was eluted in 2mL fractions using
amylose binding buffer with 25mM maltose. All buffers and samples were applied to the
column at a maximum flow rate of 2mL/min. The protein-containing fractions are
identified using UV detection of the column eluate and are pooled and stored at 4°C.
Before column is used again, it is regenerated by pumping through 5 CV of milliQ water,
5 CV of 0.5M NaOH or 0.1% SDS, and then another 5 CV of milliQ water.
Expression of MBP-RI and MBP-RI variants from the pMAL-c5E vector was
performed exclusively using the C41(DE3) strain of E. coli in RI minimal media, using
the protocol described above for expression in the pMAL-c5G vector.
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Digestion of MBP-RI and MBP-RI variant fusion proteins
MBP-RI and MBP-RI variant fusion proteins expressed from the pMAL-c5G-RI
vector were digested using Genenase I (New England Biolabs; Boston, MA). The UV280
absorbance of pooled MBPTrap elution fractions were determined using a Varian Cary
50 UV-visible spectrophotometer in a 1cm quartz cuvette. Using a theoretical extinction
coefficient for the fusion protein computed using the ExPASy ProtParam tool offered by
the SIB Swiss Institute of Bioinformatics, absorbance values were converted to protein
concentrations using the Beer-Lambert law (211) (212) (213) (214). Genenase I was
added to RI at a final concentration of 10 µg Genenase I per milligram of MBP-RI. Timecourse trials found that maximum digestion could be attained following a 36 hour
incubation at 4°C.
MBP-RI and MBP-RI variant fusion proteins expressed were digested using
recombinant light-chain enterokinase provided from two sources (New England Biolabs;
Boston, MA & R&D Systems; Minneapolis, MN). Concentrations of MBPTrap eluate
samples were measured as described above. Concentrations of 0.0001% (w/w) of New
England Biolabs’ enterokinase and 0.005% of R&D Systems’ enterokinase were used
for digestions, which were allowed to proceed at room temperature for 60 hours. DTT
was added at the beginning of the digestion to a concentration of 10mM.

Isolation and further purification of RI and RI variants
Digested MBPTrap eluate samples were diluted using anion exchange
equilibration buffer (20mM Tris-HCl, pH 7.5; 10mM DTT; 1mM EDTA) to a volume of
50mL (typically ~1:5 dilution) to reduce the NaCl concentration. Samples were then
purified via FPLC at 4°C. 5 CV of anion exchange equilibration buffer was used to pre-
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equilibrate a HiTrap Q 5mL HQ column (GE Life Sciences; Fairfield, CT). The digested
MBP/RI sample was then applied to the column. The column was washed with 5 CV of
equilibration buffer, after which bound protein is eluted using a linear gradient of
equilibration buffer starting at 0 and reaching 0.4M NaCl after 20 CV. All buffers and
samples were applied to the column at a maximum flow rate of 2mL/min. Eluate was
collected in 2mL fractions. Protein-containing fractions were identified by UV absorption
and analyzed via SDS-PAGE.
HiTrap Q eluate was further purified to fully isolate RI via gel filtration. Eluate
samples were concentrated to a volume of <5mL using 20mL, 9k MWCO Pierce protein
concentrator centrifuge tubes (Thermo Scientific; Waltham, MA). Concentrated
samples were applied to a poured column of Superdex G75 gel filtration resin (GE Life
Sciences; Fairfield, CT) and flowthrough was collected in 5mL fractions. The elution of
protein was monitored via UV absorption peaks of the column flowthrough. Proteincontaining fractions were analyzed via SDS-PAGE; samples suspected to contain RI
were concentrated to a final volume of <5mL once more using 20mL, 9k MWCO Pierce
protein concentrator centrifuge tubes. Protein concentration was again detected by
UV280 absorption and calculated using the Beer-Lambert law.

Differential scanning fluorimetry
Tm was measured in frosted PCR tubes containing a 1:5000 dilution of SYPRO
Orange concentrate (Life Technologies; Carlsbad, CA), 10mM HEPES-NaOH, pH 7.5,
150mM NaCl, and 5mM DTT, and 0.1mg/mL RI (or RI variant) in a total volume of 20µL.
Samples were placed in an Applied Biosystems 7500 real-time PCR system (Life
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Technologies; Carlsbad, CA) and heated from 25°C to 99°C in 0.74°C increments.
Changes in the fluorescence intensity were monitored with the FAM filter.
Tm values for each sample were measured by finding the temperature
corresponding to the maximum value of the first derivative of the fluorescence curve, as
performed by DeSantis and coworkers (215). First derivative data was reported by the
software bundled with the real-time PCR system and exported into Microsoft Excel for
precise determination of the minimum point in the data set.

RNase A inhibition assays using 6-FAM-dArUdAdA-6-TAMRA
Inhibition assays were performed in a clear 4-sided plastic cuvette containing
3mL of an aqueous solution of 100mM MES-NaOH (pH 6.0), 100mM NaCl, and 5mM
DTT along with 0.60µM 6-FAM-dArUdAdA-6-TAMRA (custom-synthesized by Integrated
DNA Technologies; Coralville, IA). To each cuvette, a micro stirbar (treated in 10%
nitric acid to remove ribonuclease contamination) was added. Cuvettes were placed in
a Quantum Master 4 fluorimeter (Photon Technology International; Birmingham, NJ) set
to an excitation wavelength of 492nm and a detection wavelength of 515nm
(corresponding to the excitation and emission wavelengths of FAM). After the
fluorimeter began acquiring data, RNase A was added to a concentration of 25pM.
After one minute of steady-state RNase A activity, RI or an RI variant was added in oneminute intervals in increasing concentrations. The effect on RNase A activity was
measured as the decrease in average derivative of fluorescence intensity (as reported
by the associated software) over each one-minute interval relative to RI concentration.
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RESULTS
Expression and purification of RI
Many of the expression and purification systems I tested failed to result in the
successful isolation of active RI, although the step of the process at which the failure
occurred varied. The expression of 6xHis-RI from the pET19-b vector using LB autoinduction media was successful, but not robust (Figure 19). Purification of 6xHis-RI
using Ni-NTA resin yielded only inactive protein. The presence of DTT is necessary in
solution with RI to prevent its oxidation; however, DTT also reduces the positivelycharged nickel in the resin, causing damage and leading to high amounts of nonspecific binding (Figure 20).

Figure 19: Western blot of whole cell lysate.
Cultures grown in auto-induction LB media with or
without added lactose, which induces expression of
6xHis-RI from pET19-b. “RI Standard” is recombinant
RNasin™ ribonuclease inhibitor (Promega; Madison,
WI).

Figure 20: Failed purification of 6xHis-RI from BL21(DE3) cells.
Arrowheads mark location of 6xHis-RI. “MW Std.” is Precision Plus
Protein™ dual color molecular weight standard (Bio-Rad).
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The expression of MBP-RI fusion protein from the pMAL-c5G vector was tested
in several strains of E. coli. HI-Control 10G E. coli did not express any detectable
amounts of MBP-RI. Expression was then screened in four cell types: C41(DE3),
C43(DE3), C41(DE3)-pLysS, and C43(DE3)-pLysS. pLysS-containing cells are
engineered to prevent degradation of toxic proteins and cell death due to toxic proteins
(216). The C41(DE3) and C43(DE3) cells were also co-transformed with the pGro7
plasmid, which expresses the GroEL/ES chaperone complex. The pGro7 and pLysS
plasmids both contain chloramphenicol resistance; therefore, it was not possible to
screen for pLysS-containing cells which also were successfully transformed with pGro7.
Expression of MBP-RI was apparent in all strains except for C43(DE3)-pLysS (Figure
21). C41(DE3) cells produced the most soluble, active MBP-RI by culture volume,
possibly due to the co-expression of GroEL/ES.

Figure 21: Expression of MBP-RI from pMAL-c5G in C41 and C43 E. coli strains. 3 samples of
culture were taken from each strain tested following induction of MBP-RI and GroEL/ES expression.
Arrowheads mark location of MBP-RI (~90kDa) and GroEL (~60kDa).
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Expression of MBP-RI and GroEL/ES by C41(DE3) cells was tested in two media
types: TB media and RI minimal media. TB media contains a large amount (relative to
LB) of tryptone and yeast extract, providing crude but plentiful sources of nutrients. RI
minimal media contains a variety of essential salts and a limiting carbon source.
Although the cultures grown in TB media grew faster, the recovery of soluble MBP-RI
was not significantly more fruitful than from RI minimal media, relative to the volume of
culture used. The higher cell density of TB media cultures at the end of the expression
period also lent itself to more viscous lysate that was considerably more difficult to
separate into soluble and insoluble fractions when compared to the RI minimal media
cultures. For these reasons, RI minimal media was used for all subsequent expression
cultures.
The digestion of the MBP-RI fusion protein expressed from pMAL-c5G was
inefficient (Figure 22). MBP fusion proteins expressed
from this vector are linked with a peptide containing a
site where Genenase I, an engineered protease, can
cleave the protein of interest from MBP. Incubations of
MBP-RI (crudely purified using an MBPTrap column)
with Genenase I resulted in largely undigested protein,
even after 60 hours at 4°C or 22°C. These poor
results, along with the discontinuation of Genenase I by
Figure 22: Purification of RI expressed
from pMAL-c5G in C41(DE3) cells.
“Genenase I Digest” is a sample of
MBPTrap column eluate following 36 hours
of digestion by Genenase I at 4°C. MW
Standard is Kaleidoscope™ prestained
standard (Bio-Rad).
RI Standard is
recombinant RNasin™ ribonuclease inhibitor
(Promega).

New England Biolabs, the sole provider, necessitated
the use of a new expression vector, pMAL-c5E.
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Expression from pMAL-c5E and pMAL-c5G in C41(DE3) cells yielded a similar
amount of MBP-RI. Purification of pMAL-c5E from clarified lysate via FPLC using an
MBPTrap column resulted in a crude isolation of MBP-RI along with several
contaminants, the most abundant of which was a co-expressed chaperone, GroEL
(Figure 23, lane B). Digestion of MBP-RI using enterokinase was not complete but was
more efficient than digestion by Genenase I (Figure 23, lane C).
Anion exchange chromatography using a HiTrap Q column succeeded in
removing many of the unidentified contaminants from the digested crude sample
obtained from the MBPTrap column, but did not completely eliminate the contamination
of the sample with GroEL (Figure 23, lane D). This purification step also failed in
separating RI from MBP. Further purification using size exclusion chromatography
succeeded in isolating RI to high purity (Figure 24). However, the yield of recovered RI
from this step was minimal.
Purification of the B29 and cysteine-free RI variants has been attempted using
this system, with similar results (Figures 23,24). However, both proteins eluted from the
size exclusion chromatography column earlier than wild-type RI did, relative to the
volume of elution buffer which had been passed through the column. Protein came off
at the same point as wild-type RI during the purification of both variants, but SDS-PAGE
analysis of the corresponding elution fractions did not reveal the presence of protein.
Both variants were also recovered in low yield relative to the quantity purified after anion
exchange chromatography.
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Figure 23: Crude purification of RI and RI variants using amylose affinity (MBPTrap) and anion
exchange (HiTrap Q) chromatography. MBP-RI expressed in C41(DE3) cells in RI minimal media from
vector pMAL-c5E. All lanes contain samples derived from cells expressing RI of the type shown above. A
lanes are samples of total cell extract. B lanes are samples of the MBPTrap column elution. C lanes are
samples of the MBPTrap column elution after digestion with enterokinase. D lanes are samples of the
HiTrap Q column elution. “RI Std.” is recombinant RNasin™ ribonuclease inhibitor (Promega).

Figure 24: Purification of RI and RI variants by size exclusion chromatography. Samples of
cysteine-free (CF), B29, and wild-type RI taken of elution fractions from a Superdex G75 gel
filtration column. RI standard is recombinant RNasin™ ribonuclease inhibitor (Promega).
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Thermal stability of RI and RI variants
The Tm of human RI has not been previously reported. Using differential
scanning fluorimetry, we measured a Tm for wild-type human RI of 49.1°C. The Tm of
the B29 variant of RI was not significantly different; however, the Tm of cysteine-free
variant was slightly higher than that of wild-type RI.

Variant
Wild-Type RI
B29 RI
Cysteine-Free RI

Tm
49.1
49.2
*51.1

+/0.27
0.13
0.27

Table 5: Melting temperature of RI and RI variants. Melting temperatures
(±SD) measured using differential scanning fluorimetry performed in triplicate.
Melting temperatures were measured as the temperature corresponding to the
maximum value of the first derivative of the fluorescence intensity of SYPRO
Orange.
*indicates statistically significant difference (p<0.05).

Inhibitory activity of RI and RI variants
Qualitative tests of the inhibitory activity of wild-type RI along with the B29 and
cysteine-free RI variant were performed using the 6-FAM-dArUdAdA-6-TAMRA
substrate. Eluate recovered from anion exchange chromatography for each sample
was brought to an equal concentration using anion exchange equilibration buffer. The
volume of B29 RI required to cause complete inhibition of RNase A activity was 10-fold
that of wild-type RI solution. This suggests that B29 RI has roughly 10% of the
inhibitory activity of wild-type human RI. Cysteine-free RI did not cause a detectable
reduction in RNase A activity.
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DISCUSSION
Expression and purification
Previous studies have made use of the remarkably tight binding interaction
between RI and RNase A to aid in the purification of RI (70) (179). RNase A, which is
robust and relatively easy to purify in high yields, can be covalently attached to resin
beads. When a crude protein sample containing RI is passed through these beads, RI
binds to the RNase A and sticks, while all other protein flows through. However, we
could not take advantage of this system, as we could not predict whether the RI variants
we had created would bind to RNase A. Our efforts to optimize a purification protocol
are still ongoing.
Early trials in which 6xHis-RI was expressed from the pET19-b-RI vector gave
insight into the multiple hurdles which stand in the way of successfully purifying RI.
Expressing high levels of RI, keeping it soluble and folded properly, keeping it in a
reduced state, and isolating it from other proteins are all their own separate challenges.
Screening various cell strains, media conditions, and growth temperatures led us to high
expression levels of RI that could be reproduced from culture to culture. Expressing RI
as a fusion protein with MBP and co-expressing with GroEL/ES was vital in increasing
the proportion of RI that remained soluble. Adding DTT to the culture media concurrent
with RI expression and keeping fresh DTT present at every step during and after lysis
has been important in minimizing the loss of RI to oxidation. Even the way in which we
lysed cells was evaluated; using a French press has allowed much more reliable lysis of
cells and recovery of RI.
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The isolation of soluble and active RI remains to be fully optimized. The
MBPtrap column has only facilitated the crude purification of RI (Figures 22,23). Much
of the contamination, judging by the protein size and abundance, is GroEL. The yield of
MBP-RI from the MBPtrap column has been consistent regardless of the amount of
crude lysate loaded (data not shown), indicating that we have been attempting to load it
past beyond its maximum capacity. In this case, other proteins may be getting caught
with MBP-RI in the overloaded column and eluting along with it once the MBP-RI is
freed (via the addition of maltose, which competes MBP off the maltose covalently
bound to the column resin). Lowering the amount of lysate added at one time may
increase the overall yield while reducing the overall contamination of other proteins in
the eluate due to non-specific binding.
Another tactic that may reduce the amount of GroEL that is eluted along with
MBP-RI is the addition of either an ATPase or additional ATP to the cell lysate prior to
purification. ATP triggers multiple changes in the structural conformation of GroEL
which, in vivo, allow for the association of GroES and a shift from a hydrophobic proteinbinding state to a hydrophilic protein-folding state (217). We cannot be sure which
conformation is dominant in our lysate samples but it is possible that increasing or
depleting the ATP concentration may discourage the non-specific binding of GroEL
within the MBPTrap column.
Anion exchange chromatography using the HiTrap Q column has resulted in only
a marginal degree of purification. Proteins elute from an anion exchange column
sequentially, based on their isoelectric point (or pI; a determinate of a protein’s net
charge at a given pH). Proteins with different isoelectric points elute from the column at
different concentrations of NaCl (218) (219). The pI of MBP is 5.1, and pI of GroEL is

68
4.8; both of these are close to the value of 4.7 for RI, which jeopardizes our efforts to
purify RI from MBP using this method (220) (221). This may explain why both proteins
have eluted along with RI from the HiTrap Q column simultaneously (Figure 23);
however, this has not always occurred (Figure 22). It appears that lower contamination
in the sample eluted from the MBPTrap column lends itself to lower contamination from
the HiTrap Q column. Perhaps the solutions for decreasing the non-specific binding
during the MBPTrap purification described above will be sufficient to solve this problem.
If not, other purification options are available, such as hydrophobic interaction
chromatography, which separates proteins based on their exposure of hydrophobic
amino acids rather than their isoelectric point (222).
Faced with the failure of anion exchange chromatography to completely purify RI
from MBP once digested with enterokinase, we turned to size-exclusion
chromatography. This led to a large loss in overall protein yield. It is our hope that we
can avoid the time-intensive process of size-exclusion chromatography all together
once we optimize the prior two steps of RI purification.

Thermal stability and inhibitory activity of RI variants
In replacing the cysteines of RI in various ways, we sought to answer a basic
question about this protein: have these cysteines been selected for because they play
an important structural role, because they are necessary for binding ribonucleases, or
because it was important that RI be sensitive to oxidation? Although our results so far
in characterizing our RI variants are still preliminary, we can still make some interesting
(although equally preliminary) conclusions in this regard.
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The conservative substitution of various similar amino acids in human RI does
not decrease the structural stability of the protein. Five cysteines are replaced in the
B29 variant of RI, all in a conserved position throughout the repeating structural
modules. However, these replacements did not change the Tm of the B29 variant in a
significant way (Table 5). Furthermore, the total replacement of every cysteine in RI led
to an increase in overall structural stability, as measured by a significant increase in the
Tm. It is important to note here that CD spectroscopy will be necessary to demonstrate
that this variant still exists in the same tertiary structure as wild-type RI. However, if it
does, we have shown that the presence of cysteine in RI serves to decrease the overall
structural stability.
By its design, the cysteine-free RI variant is not susceptible to cysteine-mediated
oxidation. At the same time, however, ribonucleases are not susceptible to cysteinefree RI, as we have been unable to detect that this variant has any inhibitory activity.
While we have not yet assessed the oxidative sensitivity of the B29 variant, it
nevertheless shows reduced inhibitory activity against ribonucleases (relative to wildtype RI) after the substitution of an intermediate amount of cysteines.
Based on these findings, we propose that the susceptibility of RI to oxidation is
an integral part of its biological function. If it is the same residues, the cysteines, which
are necessary for inhibitory activity and oxidation sensitivity, it is possible that these
residues have been selected for and preserved in order to maintain both phenotypes
simultaneously. At least two of these cysteines are known to be important in noncovalent interactions with ribonucleases, but they also may contribute to binding in
another fashion . RI relaxes its structure and stretches open when it binds to
ribonucleases (72). If this stretching is necessary to accommodate binding, then the
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cysteine-mediated structural destabilization we have identified may be necessary for the
activity of RI. Variants stabilized by the removal of cysteine may be too rigid to “make
room” for ribonucleases to bind.
The importance of simultaneously maintaining both of these traits is not clear in
either the “intracellular sentry” or anti-oxidant theories of the biological purpose of RI
(129) (144). However, in light of the recent discovery of its role in a cellular stress
pathway in which the oxidation of RI is necessary to allow for the free activity of
angiogenin, such a relationship appears to exist (Figure 25) (147). If the oxidation
sensitivity of RI goes hand-in-hand with its ability to modulate ribonucleases, and this
interaction is essential, then it is also possible that ribonucleases which are betterinhibited by an oxidation-sensitive RI have co-evolved with RI.
Fully-active variants of RI with reduced sensitivity to oxidation have been created
in the past by substituting alanine for cysteine (102). However, the only cysteines that
were successfully replaced in such a way were cysteines 328 and 329, which are

Figure 25: A hypothesis for the evolutionary purpose of rapid oxidation-induced denaturation
and inactivation in human RI.
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adjacent to each other. Only two pairs of adjacent cysteines exist in human RI (Figure
12), and it is possible that these pairs contribute more strongly to the oxidation
sensitivity of RI than to the inhibitory activity of RI. The proximity of the thiol groups in
these adjacent pairs makes it more likely for them to form a disulfide bridge, one which
creates an eight-membered ring which destabilizes the local structure (102).
Importantly, the variants produced by the substitution of this adjacent pair were not
completely immune to oxidation. Furthermore, porcine RI has only one such pair, and
rat RI does not contain any adjacent cysteine residues (107) (223). For these reasons,
it is possible that these adjacent pairs of cysteines have arisen recently in the human
lineage and provide added oxidation sensitivity to what is already an oxidation-sensitive
protein.
The further development of this hypothesis will require us to complete the
expression, purification, and characterization of all six RI variants. As we move towards
this goal, we also find ourselves completing a project which may serve as a hub to
begin other investigations into the biological properties of RI. If a variant of RI is
successfully produced that has reduced sensitivity to oxidation yet maintains its
inhibitory activity, the pathology of its substitution for wild-type RI in vivo could allow us
to identify the exact processes in which RI is important. Another interesting route to
explore is whether or not any of our variants maintain affinity for the anti-tumor protein,
PTEN. Does inhibitory activity against ribonucleases or oxidation sensitivity correlate in
any way to the ability to interact with this important protein? Changes in the ability of
our variants to interact with Drosha could also provide meaningful insights into how RI
modulates microRNA processing. Last, but not least, the maintenance of tertiary
structure in cysteine-free RI would suggest we have created a highly oxidation-resistant,
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stable, and modular scaffold for protein engineering. All of these possibilities keep us
excited and driven to continue working to discover more about the role of RI in the
chaotic and amazing biochemical realm of life.
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